312 related articles for article (PubMed ID: 28973087)
21. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
Feng X; Berklein F; Rane PB; Habib M; Lin PJ
Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
[TBL] [Abstract][Full Text] [Related]
22. Outcomes, Access, and Cost Issues Involving PCSK9 Inhibitors to Lower LDL-Cholesterol.
Whayne TF
Drugs; 2018 Mar; 78(3):287-291. PubMed ID: 29396831
[TBL] [Abstract][Full Text] [Related]
23. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
[TBL] [Abstract][Full Text] [Related]
24. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
[TBL] [Abstract][Full Text] [Related]
25. Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.
Shah P; Glueck CJ; Jetty V; Goldenberg N; Rothschild M; Riaz R; Duhon G; Wang P
Lipids Health Dis; 2016 Aug; 15(1):132. PubMed ID: 27538393
[TBL] [Abstract][Full Text] [Related]
26. A regional analysis of payer and provider views on cholesterol management: PCSK9 inhibitors as an illustrative alignment model.
McCormick D; Bhatt DL; Bays HE; Taub PR; Caldwell KA; Guerin CK; Steinhoff J; Ahmad Z; Singh R; Moreo K; Carter J; Heggen CL; Sapir T
J Manag Care Spec Pharm; 2020 Dec; 26(12):1517-1528. PubMed ID: 33251993
[No Abstract] [Full Text] [Related]
27. [PCSK9 inhibitors (PCSK9i), a new opportunity for cardiovascular prevention: clinical and regulatory aspects and access to therapy.].
Arca M
Recenti Prog Med; 2019 Sep; 110(9):401-411. PubMed ID: 31593176
[TBL] [Abstract][Full Text] [Related]
28. Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D Plans.
Kazi DS; Lu CY; Lin GA; DeJong C; Dudley RA; Chen R; Tseng CW
JAMA Cardiol; 2017 Oct; 2(10):1164-1166. PubMed ID: 28903137
[TBL] [Abstract][Full Text] [Related]
29. Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans.
Derington CG; Colantonio LD; Herrick JS; Cook J; King JB; Rosenson RS; Poudel B; Monda KL; Navar AM; Mues KE; Stevens VW; Nelson RE; Vanneman ME; Muntner P; Bress AP
J Am Heart Assoc; 2021 Apr; 10(8):e019254. PubMed ID: 33821686
[TBL] [Abstract][Full Text] [Related]
30. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
31. Integrated specialty pharmacy yields high PCSK9 inhibitor access and initiation rates.
Reynolds VW; Chinn ME; Jolly JA; Kelley TN; Peter ME; Choi L; Nwosu S; Leon BC; Zuckerman AD
J Clin Lipidol; 2019; 13(2):254-264. PubMed ID: 30745204
[TBL] [Abstract][Full Text] [Related]
32. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Yazdi D; Elliott-Davey M; Mues KE; Bhatt DL; Kosiborod MN;
Am Heart J; 2020 Jan; 219():70-77. PubMed ID: 31726422
[TBL] [Abstract][Full Text] [Related]
33. [Eligibility for the indication of PCSK9 inhibitors according to the recommendations of different scientific societies].
Siniawski D; Masson W; Rossi E; Damonte J; Halsband A; Pizarro R
Medicina (B Aires); 2019; 79(2):104-110. PubMed ID: 31048275
[TBL] [Abstract][Full Text] [Related]
34. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
Sabatine MS; Giugliano RP
JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
[No Abstract] [Full Text] [Related]
35. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
[TBL] [Abstract][Full Text] [Related]
36. Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States.
Inoue K; Figueroa JF; DeJong C; Tsugawa Y; Orav EJ; Shen C; Kazi DS
Circ Cardiovasc Qual Outcomes; 2021 May; 14(5):e007521. PubMed ID: 33966446
[TBL] [Abstract][Full Text] [Related]
37. New Drugs for Lowering LDL-Cholesterol.
Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
[TBL] [Abstract][Full Text] [Related]
38. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
39. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
[TBL] [Abstract][Full Text] [Related]
40. PCSK9 inhibitors and managing cost in the managed care setting.
Stadler SL; Cook TJ
Am J Manag Care; 2017 Jun; 23(9 Suppl):S149-S155. PubMed ID: 28978220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
